4 recruiting, 3 active not recruiting, 1 enrolling by invitation. 8 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 8 | Recruiting 4, Active not recruiting 3, Enrolling by invitation 1 |
| Phase 2 | 2 | Active not recruiting 1, Recruiting 1 |
Follow XL092: new trials by email Literature Review of XL092 trials Research Report on XL092
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease Zanzalintinib, Pembrolizumab (+) Berahyaluronidase alfa, Placebo - Colorectal Cancer | Phase 3 | Recruiting | Exelixis | 600 | 2026-12-18 | 2026-11-12 |
| Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study Cabozantinib, Zanzalintinib, Atezolizumab - Cancer, Renal Cell Carcinoma (RCC) | Phase 3 | Enrolling by invitation | Exelixis | 5000 | 2026-07-30 | 2026-10-28 |
| A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034) Belzutifan, Zanzalintinib, Placebo - Carcinoma, Renal Cell | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 758 | 2026-04-09 | 2026-11-13 |
| A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033) Belzutifan, Zanzalintinib, Cabozantinib - Renal Cell Carcinoma | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 904 | 2025-11-26 | 2026-11-12 |
| Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors Zanzalintinib, Everolimus - Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET) | Phase 2 / Phase 3 | Recruiting | Exelixis | 440 | 2025-07-21 | 2026-10-30 |
| Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Zanzalintinib, Zanzalintinib-matched Placebo, Pembrolizumab - Head and Neck Squamous Cell Carcinoma | Phase 2 / Phase 3 | Active not recruiting | Exelixis | 600 | 2024-06-07 | 2025-08-17 |
| Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma XL092, Nivolumab, Sunitinib Malate - Non-Clear Cell Renal Cell Carcinoma | Phase 3 | Active not recruiting | Exelixis | 317 | 2023-01-01 | 2026-07-29 |
| Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer XL092, Atezolizumab, Regorafenib - Colorectal Cancer | Phase 3 | Active not recruiting | Exelixis | 901 | 2022-09-07 | 2026-07-17 |
Carcinoma, Renal Cell (3) · Colorectal Neoplasms (3) · Adenoma, Islet Cell (1) · Carcinoma (1) · Carcinoma, Hepatocellular (1) · Microsatellite Instability (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Neuroendocrine Tumors (1) · Prostatic Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1)
Exelixis (6) · Merck Sharp & Dohme LLC (2)
United States (8) · Australia (6) · France (6) · Germany (6) · Poland (6) · South Korea (6) · Spain (6) · United Kingdom (6) · Brazil (5) · Italy (5) · Argentina (4) · Belgium (4) · Chile (4) · Czechia (4) · Greece (4)
PMID 39041200, PMID 40008409, PMID 40248950, PMID 41130252, PMID 42803451
2025 (1)